---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-015880"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T04:43:25.920525+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "medium"
source: SEC EDGAR
---

# Gyre Therapeutics posts updated corporate presentation; no material financial disclosures

## Summary
- Presentation titled 'Developing Anti-Fibrotic Therapeutics for Chronic Organ Diseases' made available on company website.
- No new financial data, guidance, or clinical trial results disclosed in the filing or exhibit.
- Presentation is furnished under Regulation FD; not deemed filed for SEC purposes.
- Company continues to focus on fibrotic disease therapies; no changes to strategy announced.

## SEC filing metadata
- accession: 0001140361-25-015880
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036125015880/0001140361-25-015880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036125015880/ef20048044_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-015880
- JSON: https://secwatch.observer/filing/0001140361-25-015880.json
- Plain text: https://secwatch.observer/filing/0001140361-25-015880.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.